Welcome to the Revance Therapeutics first quarter 2022 financial results and corporate update conference call. At this time, all participants are in a listen-only mode. Following management prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star followed by one on your touch tone phone. If anyone has difficulty hearing the conference call, please press star zero for operator assistance. As a reminder, this call is being recorded today, Tuesday, May 10, 2022. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance. Please go ahead. Thank you, Nika. Joining us on the call today from Revance are Chief Executive Officer Mark Foley, President Dustin Sjuts, and Chief Financial Officer Tobin Schilke. During this conference call, management will make forward-looking statements, including statements related to the regulatory process and potential approval and timing of approval for DaxibotulinumtoxinA for Injection in glabellar lines and as therapeutic indications. Plans related to RHA Redensity and the OPUL platform, the benefits to aesthetic practices and patients of our products and services, our financial performance, 2022 guidance, expected cash runway, strategic priorities, and capital allocation plans, our market and revenue opportunity, and the market demand for our products and services, portfolio growth, and our business strategy, planned operations, and commercialization plans. With that, I will turn the call over to Mark Foley, Chief Executive Officer of Revance. Mark? Thank you, Jessica. Good afternoon, everyone, and thank you for joining our first quarter 2022 financial results conference call. We had a very productive start to the year, delivering on several important objectives. First, and most importantly, the FDA accepted our BLA resubmission for DaxibotulinumtoxinA for Injection for glabellar lines. With the acceptance, we received a new PDUFA date of September eighth, 2022, which reflects a Class 2 resubmission and will include a re-inspection of our manufacturing facility. This important regulatory milestone was made possible by the completion of our new working cell bank qualification package in Q1. I would like to thank the technical operations, clinical, and regulatory teams for all of their hard work in achieving this objective. Having a PDUFA date is key. This will be the first time since our deferred action in November 2020 that we are working towards a specific date. We will continue to work with the FDA to facilitate their timely review while recognizing that we are now one step closer to a potential approval later this year. Another priority was to strengthen our balance sheet and extend our cash runway in order to support our strategic priorities of getting our lead asset approved, increasing sales of our RHA Collection, and enhancing our customer relationships with OPUL. To that end, we were pleased to achieve this key objective by completing a $300 million non-dilutive debt financing with Athyrium Capital Management and raising an additional $31.8 million in net proceeds from our ATM offering program. With our recent financing activities and the additional notes that we can issue with the FDA approval of DaxibotulinumtoxinA for Injection, our cash runway can be extended into 2024. We believe we are well positioned for the significant opportunity ahead at Revance. In aesthetics, we believe our innovative portfolio of products and services will allow us to capitalize on the multi-billion-dollar market opportunity that continues to grow at a healthy clip. Core of our portfolio is our long-acting neuromodulator, and we're both ready and excited to bring our drug product to market. Our commercial infrastructure is strong, anchored by our proven 100+ person sales team, our over 3,500 aesthetic accounts, which continue to grow, and our industry-leading training and experience center at our Nashville corporate headquarters. Together with our differentiated commercial strategy and complementary portfolio offering, we believe DaxibotulinumtoxinA for Injection has a solid foundation for commercial success. Additionally, in advance of the anticipated approval of our neuromodulator, we've entered into partnerships with two experienced fill-finish contract manufacturing organizations to help support our production needs. This is in addition to the drug substance and drug product we will be manufacturing at our Northern California facility. Turning to therapeutics, we continue to be excited about the opportunity for our long-acting neuromodulator. Currently, we are ready to file a supplemental BLA for DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia following the FDA approval of our indication for glabellar lines. We successfully completed our ASPEN Phase III clinical program in November of last year and have been actively preparing our supplemental filing. Given the encouraging data from our clinical programs, which showed that our drug product was generally safe, effective, and had a long duration profile, we look forward to our potential opportunity in therapeutics as well. The indication for cervical dystonia will be our entry point into the $1.2 billion global muscle movement disorder category, which has a compound annual growth rate in the high single digits. In summary, we have several important near-term catalysts across our business, and execution will continue to be key. We remain bullish on the long-term market opportunity for Revance, and in particular, on our ability to lead the long-acting neuromodulator segment. I would like to thank all members of the organization for their continued dedication and support in advancing our corporate objectives and priorities. With that, let me turn the call over to Dustin, who will cover our performance in the first quarter. Dustin? Thank you, Mark. I'd like to start by highlighting again the significant regulatory milestone we've achieved with the FDA's acceptance of a resubmission. With the September eighth PDUFA date, we are looking forward to potential approval and launch of our neuromodulator in the not-too-distant future. The cornerstone of the Revance aesthetic strategy is to foster long-term partnerships with exclusive providers and provide product innovation that delivers the best consumer outcomes. We believe that DaxibotulinumtoxinA for Injection, once approved, will anchor that strategy, build on our track record with RHA and OPUL, and position us for accelerated growth in the years ahead. Now turning to our performance. Growth continued across our aesthetics portfolio in the first quarter, with our RHA Collection reaching all-time sales of over $100 million just after completing its first year of commercial launch. RHA sales for the quarter totaled $20.8 million, up 78.9% year-over-year, driven by solid account growth and increased productivity within our accounts. Despite the first quarter being the slowest period of the year for aesthetic procedures, we continued to drive consumer awareness and adoption through our targeted sales efforts and live and virtual training sessions at our national headquarters. Across our products and services portfolio, total accounts grew to over 3,500 at the end of the first quarter. We have a number of training and education experiences planned over the coming months to continually drive product adoption and expertise, especially as we prepare the launch of RHA Redensity in Q3 of this year. We are excited to bring to market the first and only FDA-approved filler for both superficial dermal and dermal injection of dynamic perioral rhytids or lip lines. RHA Redensity has the most stretch of the RHA Collection and has a low rate of modification to deliver a natural look that is consistent with the rest of the collection. Given its unique formulation properties, injectors can fine-tune the treatment of lip lines. We believe the product will be a great addition to the RHA Collection, providing injectors with more treatment options to optimize outcomes. Turning to our fintech platform, gross payment volume totaled $154 million in the first quarter, up 66.4% from the same period last year, driven by account growth and higher transaction volumes processed. On a trailing twelve-month basis, GPV was approximately $570 million. The team continues to work hard to enhance OPUL's platform experience. We are currently working on building practice loyalty capabilities with memberships and improving insights with transaction data. All the new features under development are designed to help practices grow their business and, in turn, allow us to deepen our relationships with our practice providers. In short, we are excited about the future of the OPUL platform and its ability to unlock additional value for Revance. With that, I'll turn the call over to Toby to cover our first quarter financials. Thank you, Dustin. Before I discuss the results for the quarter, I'd like to review our recent financing activities and the balance sheet. As Mark mentioned, enhancing our financial flexibility ahead of the potential approval of our neuromodulator was a key objective for 2022, and we were pleased to achieve this goal despite being in a challenging financial market. In March, we closed a $300 million note purchase agreement with Athyrium Capital Management as part of our long-term financing strategy to support our operating plan. The agreement will not only serve as an important bridge to the FDA approval and commercialization of our neuromodulator, but also support the growth of the rest of our aesthetics portfolio. I won't go into all the details on the call, but we'll provide brief highlights of the transaction. Tranche one of $100 million was issued at closing, providing us with immediate liquidity. Tranche two of another $100 million will be available at our option, subject to the FDA approval of our neuromodulator within 18 months of closing. Tranche three, an uncommitted $100 million available at our option within 24 months of closing and tied to revenue targets for our neuromodulator. Further details of the transaction are available in the note purchase agreement that was filed with our Form 10-Q earlier today. With the $100 million in notes issued and an additional committed $100 million available subject to the FDA approval of DaxibotulinumtoxinA for Injection for glabellar lines, our cash runway can be extended into 2024. In addition to our debt financing, we raised $31.8 million in net proceeds year to date from our ATM program, $8.9 million of which was raised during the first quarter. With the total shares of common stock issued, we have effectively completed our $125 million ATM offering that was initiated in 2020. Total cash equivalent, and short-term investments at quarter end was $262.6 million. For the time being, our cash preservation measures that are gated to the FDA approval of DaxibotulinumtoxinA for Injection remain unchanged, and disciplined capital allocation will continue to be a priority. Turning to the results for the first quarter, total revenue was $25.3 million, representing an increase of 89.9% from $13.3 million in the same period in 2021. Revenue growth was primarily due to increased sales of the RHA Collection of dermal fillers. Revenue for the first quarter included $20.8 million of product revenue from the RHA Collection, $3.6 million of collaboration revenue from our partnership with Viatris, and $0.9 million of service revenue from our fintech platform. Operating expenses for the first quarter were $87.5 million compared to $83.3 million for the same period last year. Excluding depreciation and amortization and stock-based compensation, non-GAAP operating expenses were $59.9 million for the first quarter, representing a 7% decline over the same period last year due to lower SG&A expenses as a result of our cash preservation measures, partially offset by higher R&D costs related to pre-commercial manufacturing and quality activities related to our neuromodulator and product development for OPUL. As a reminder, we project R&D expenses in 2022 to be primarily driven by manufacturing costs for DaxibotulinumtoxinA for injection, which according to GAAP accounting standards are expensed as a period cost until the drug product is approved. As for our operating expense outlook, we are confirming our previously announced GAAP and non-GAAP operating expense guidance for 2022. Finally, Revance's shares of common stock outstanding as of April 29, 2022, were approximately 72.8 million, or 80.4 million fully diluted shares, excluding the impact of convertible debt. With that, I'll turn the call back over to Mark. Thank you, Toby. In closing, we are pleased with the meaningful progress we have made from a regulatory, financial, and operational perspective, all positioning us for growth and opportunity ahead. We remain focused on delivering on our strategic priorities for 2022, with the top priority being obtaining FDA approval for our highly anticipated DaxibotulinumtoxinA for Injection for glabellar lines. Also, I'd like to thank all of our stakeholders for their continued support of Revance. With that, I will now open the call up for questions. Operator? As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound or hash key. Please stand by while we compile the Q&A roster. Your first question comes from the line of Ken Cacciatore from Cowen and Company. Your line is now open. Hey, team. Congratulations on all the progress. Just a couple of questions. The first is just wanted to see if the re-inspection has actually been through. Second, I know, Mark, in the past, you talked about a little bit of a paced launch of DAXI assuming approval. Can you just talk about what that entails as you think about kind of what accounts you will go to, level of training, and then maybe discuss with us, in absence of sales early, kind of what metrics we should be focused on. Lastly, on approval, I know you have a 100-person sales team now. Can you just give us a sense of where that is going? Thanks so much. Sure, Ken. First off, could you highlight? I missed the first question a little bit. Something about re-inspection? Yeah, just wondering if it's been scheduled yet, actually formally scheduled. Okay. Got you. Perfect. Okay. Let me hit those in order. First one on the re-inspection. You know, consistent with our company policy, we're not gonna be commenting on the status of the ongoing BLA review process or interactions with the FDA. We did sort of break from that, given the COVID environment, and some of the FOIA requests that were made public, so we felt like we needed to comment on that. Really the next time that you'll hear from us will be around the, you know, PDUFA action date, or should we hear something sooner. Of course, if we hear anything material between now and then, we would also put that out. You know, we're gonna stick with kind of prior company policy, and we'll continue to, you know, be as responsive to the FDA as possible to, you know, support, you know, our planned approval. In terms of the pacing of the launch of DAXI and the metrics, you know, if you think about it, we've long talked about, you know, DAXI, because of its performance profile, has a unique opportunity in the market, but it is gonna be different. It's gonna be really critical that we use this initial launch phase to make sure that we get it in the hands of a targeted group of practices to let them use it in a real-world setting. You know, historically, we've talked about this phased launch, where the early phase is going to be in the hands of a small group, and then we'll expand that to a little broader group based on the learnings that we have. We think this is the right way to build the brand over long term. This is different than other competitor products where there's no difference in terms of, you know, sort of the reconstitution or the performance of the product. You know, we think this is the right way to launch the product. It's very consistent with what we did with the RHA line of fillers, too. We started with a very phased launch, all geared towards ensuring the right long-term outcomes. Once we get sort of that foundation built, then we can start to accelerate it. You know, the good news is we now have over 3,500 accounts where we've got relationships between both our products and services. We'll have no shortage of accounts that we can leverage once we get through this initial phase. You know, on the metric side of it, I think in the early phase, we'll talk about you know, sort of some of the learnings from the early rollout. We'll certainly signal once we feel that we're ready to start more of the ramp, kind of when that is. In terms of the sales force, you are right. We've got roughly a 100-person sales organization. Given that we're gonna start in more of a staged approach with this launch, we will certainly look to expand the sales force. Once we feel like we're ready to accelerate into that next phase of broad commercial adoption. We'll also wanna make sure that we pace that with, you know, what's the right time in terms of, you know, account, you know, changing up some of the territories and expanding so that we do that in a very thoughtful way. Thanks so much. Great. Thanks, Ken. Your next question comes from the line of Seamus Fernandez from Guggenheim. Your line is now open. Thanks for the questions, guys. Congrats on the quarter. Just wanted to get, maybe a little bit more color, as you think about the timing of launch. You know, if we were to actually see, you know, full approval on the PDUFA on September 8, can you just kinda walk us through what needs to happen, you know, from that point in time to then execute the launch officially? You know, and I know it's gonna be measured, but maybe you can just walk us through, you know, training of the sales force that would need to happen incrementally. And then just, you know, when you would anticipate actually launching. I think in the past, Mark, you had talked about maybe the initial rollout being to a concentrated group of physicians, maybe something in the hundreds, and then expanding sequentially and more broadly as physicians got experience. I think that's consistent with what you just talked about, but I didn't know if those numbers were a reasonable expectation. Then just lastly on the fillers, can you just walk us through a little bit, really good performance in what's seasonally typically a kind of seasonally weak quarter or a weaker quarter in first quarter. Second quarter, very strong. Just wondering how the trends are looking at this point, as we're halfway through the quarter. Thanks. Sure. Maybe I'll answer the beginning of your first question, then turn it over to Dustin on some of the sales and then hit your second question after that. You know, in terms of the rollout, you know, post-approval, like you said, if we receive approval on September eighth, theoretically, then there's gonna be a little bit of time after we receive that approval to get the final packaging and the labeling and everything squared away and put on the boxes so that we can ship it. You got, you know, a few weeks there that you have to account for on the logistics side of it. After that, we talked about going to a very small concentrated group of physicians to again, get it in their hands and have them, you know, provide us feedback on a real-world setting. Following that phase, we would then move to this broader group that you talked about. They, you know, with RHA, we said that with, you know, roughly 100 or so customers, we'll right size to what we think that group is for this next phase to take that learnings from that initial group, use it in a broader setting, and then take that learning and experience to refine sort of, you know, the training and education process that will be needed to roll it out. You know, again, we've made a pretty sizable investment in Nashville with our corporate training and education center to be able to make sure that we're providing world-class training. You know, given sort of the performance profile of the product, we think that, you know, we'll get high levels of engagement from physicians and injectors to wanna make sure that they learn all the tips and tricks that will be important to getting a successful outcome. Dustin, maybe you can talk a little bit about sales force and any other logistics associated with it. Yeah. No, thanks, Mark. Obviously, the good and bad is we've had a little extra time here. We are very well prepared from a sales force training perspective. We were able to train on a lot of the clinical data already, as well as the toxin market landscape, right? Those are data that we can train on now, so they have been brought up to speed with that while constantly kinda getting up to speed with all the new clinical programs and things that are ongoing. We feel like we've got a jump start from a sales force training perspective. We will bring them together to train them on then the marketing messaging, the labeling, those sorts of things specific to DAXI. We believe that we can do that in tandem with some of these launch phases that Mark said. I think we'll also be able to leverage the national experience to potentially expand a bit of the early numbers in those groups. We've made that investment allow us to be very efficient with our training and accommodate significantly more numbers than we're able to do with the RHA preview. It will be focused on obviously launching the product with the right accounts as with the right outcomes. We feel like we'll be in a really good position to get started early. Mark, do you wanna hit the RHA trends? Yeah. You know, Seamus, to your question on just sort of what we're seeing out there in the market and trends. Yeah, I mean, as you noted, Q1 is seasonally a down quarter, certainly relative to Q4. We were encouraged based on the performance of our RHA sales in Q1 that, you know, the degradation of Q4 to Q1 was, you know, less than what is typically the industry standard. I think that reflects the fact that we're still in launch and growth mode. We continue to be encouraged by what we're seeing. You know, here we are, you know, a little over a year into launch, generating almost $100 million from the launch, launching three SKUs. We're really proud of what the commercial team has accomplished out there. You know, we continue to be encouraged by the trends that we're seeing in the market. In Q2, you know, we're continuing to see, you know, a good market out there, you know, good demand for injectables. I know there's, you know, a little bit of question around sort of rising interest rates and COVID resurgence, but thus far we continue to feel like the market's, you know, steady as she goes and we're continuing to see, you know, good growth there. We continue to be cautiously optimistic as we move through the year in terms of how we think the injectable market's gonna perform. Great. Thanks, guys. Great. Thanks, Seamus. Your next question comes from the line of David Amsellem from Piper Sandler. Your line is now open. Hey, thanks. Just have a couple. First on RHA Redensity, can you just talk about how you're sizing up that opportunity and specifically the extent to which that expands the overall peak sales potential of the RHA franchise? That's number one. Number two, just a high-level question about the toxin market. You know, we've seen some pretty strong growth out of the market leaders and even strong growth with some smaller players here. I guess the question here is, you know, do you see a lot of that growth coming from prestige accounts, the kind of accounts that you're gonna be targeting initially? Is that coming from just an expansion of just the number of injectors? As you look at that, you know, how does that inform how you're thinking about early commercialization and your efforts surrounding DAXXIFY? Thanks. Great. Thanks, David. I'll go ahead and have Dustin answer your first question about Redensity, you know, how we size the market and how we think about, you know, what it might do from an expansion opportunity. Dustin, why don't you hit that one? Yeah, thanks, David. We're really excited about the launch of RHA Redensity. It will be our fourth gel in the marketplace since launch, and we'll be the first company that has four unique gel properties in the market that early from introduction in the United States, which allows us to really address the ever kind of changing needs of the practitioners in the United States. From a market perspective, it's really difficult in the dermal filler market to kind of tease them out indication by indication because so much of the use is outside of the kind of FDA labeled indications. We feel like the RHA Redensity line is unique in that it is able to be the first and only product that's injected superficially and mid-dermally, which allows for that icing on the cake effect across a variety of locations. It's a great fit. It allows us to continue to be innovative in the space, have something new to talk about and train on, and also continue to address the evolving needs. We feel really good about it being that product that helps us continue that relevancy and shows the strength of the entire range of the product. Yeah, on your second question, David, regarding the toxin market and the strength there and where's the growth coming from, I mean, we're seeing the same trends, right? I think that, you know, if you look at sort of the forecast over time, I think collectively as an industry, we continue to think we're gonna see good growth in the facial injectable category. I think it's gonna be a combination of all the factors that continue to drive it today. You've got some younger people that are engaging in sort of rejuvenation. You've got, you know, people that are deciding to finally engage in aesthetics because they wanna retain the best version of themselves, and I think that's a function of a good, healthy market. With more competition and more awareness, I think you're gonna see more people come in. We would expect also with our long-acting neuromodulator that it's going to stimulate another narrative out in the market around sort of the benefits of toxins overall. I don't know that there's any sort of unique catalyst right now. I think it's the collective effect of, you know, the industry further investing dollars and bringing more people into the fold. You know, some of the growth is impacted by price increases that some of the competitor companies have taken. I think you're seeing, you know, not only good increase in overall procedures, but some lift due to price as well. I don't think any of this changes our strategy. You know, when we've done all our market survey work, we continue to believe that the value proposition of a long-acting neuromodulator, you know, really resonates with people that are seeking a toxin treatment. We think that, you know, we'll continue to benefit from the overall growth and that, you know, a healthy subset of that group is, we believe, going to be interested in the value proposition of a long-acting neuromodulator. You know, we feel that the strategy that we've had in place for some time continues to be the right strategy. Even with the market growth, we don't see any need to change that. Thanks, guys. Great. Thanks, David. Your next question comes from the line of Annabel Samimy from Stifel. Your line is now open. Hi. Thanks for taking my question. I was wondering, as far as the training is concerned, is there anything you can share with us on the product profile that you understand to be different that physicians really need to be trained on outside of duration? You already mentioned that there's some reconstitution that's required. I know training for new neuromodulators have tripped up others in the past. How do you feel about the profile here and how easy it is to train practicing physicians on this one? That's, I guess, question number one. What kind of barriers do you have there for adoption? Just to reconfirm, not sure if you're gonna even answer this, but can you tell us whether the FDA, the current review by the FDA is strictly based on the manufacturing changes that you made and everything else has been negotiated, i.e., this is strictly a manufacturing thing? I guess those are my two questions. The others have been answered. Thank you. Yeah. First on the training side of it, I mean, I think we've got the benefit of having seen other companies launch into the marketplace with sort of different dilution or reconstitution and a variety. We're acutely aware of the importance of making sure I think one of the big advantages that we have is the unique performance profile. In any time you're asking somebody to change behavior or learn something new, the question is it worth their time to invest in doing something different? We believe that based on the duration profile of our neuromodulator that the answer is yes. We are very aware of the fact that, you know, everybody has their own dosing, right? Our dosing is different than others. We need to make sure that our injectors understand exactly how to reconstitute, you know, what that, you know, sort of injection pattern was for the clinical trials. Then that brings us back to sort of the strategy of working with a small group of sort of leaders in the field to, you know, get some real-world feedback and then use those learnings again to, you know, share that with that next group that we go into. You know, we think we are being very thoughtful and we'll be very methodical. As we talked earlier, that's why for us out of the gate, it's not so much how much revenue we generate initially, it's how do we ensure that we get really good clinical outcomes? Because with good clinical outcomes, we believe that, you know, we've got a great opportunity to be a meaningful player in this market. Frankly, it's not too different than the launch of the RHA fillers. You know, as good as the RHA filler line is, you know, if you look at how physicians are injecting that, you know, there have been some tweaks that these injectors have made. They sometimes tend not to go quite as deep and bury it on the bone and do some things there. We've had to be really thoughtful while remaining on label to make sure that people understand the subtle differences. I think that, you know, that's showing up in the performance of the numbers. You know, based on those learnings, we think we've got the right strategy in place, and we've also believed that we've set it up to make sure that we are learning out of the gate versus trying to chase a number. On the second one, in terms of the FDA, in terms of the review, I mean, if you look at the CRL that we received, the observations were limited to, you know, sort of manufacturing. There were the five observations. You know, we had a Type A meeting. We indicated that, you know, what the agency wanted us to do was to provide the qualification for the new working cell bank. We also previously stated that, you know, heading into the deferral where we were waiting for the inspection, everything else had already been addressed by the agency, so, you know, clinical, non-clinical, CMC, label. We continue to feel very good about where we are, and are, you know, looking forward to, you know, working closely with the agency, towards our PDUFA date. Okay. If I could just ask one more follow-up on the training, question. Is there, I guess I know it's hard to put a timeline on it, but for the training, like, at what point, is it just initial feedbacks that you're getting in terms of the initial performance, or is this gonna take longer 'cause you have to sort of watch the duration and see how the product performs over the course of the six months, get some feedback from physicians on how satisfied the patients were? Like, I just wanna kind of understand the timeframe that we should think about this training period, let's say. Yeah, no, in talking with our, you know, physicians, I think that given sort of the amount of clinical data that's been generated demonstrating the duration profile of the product, I think what they're very interested in is sort of that acute look, right? You inject the patient, you wait a couple days, you wait to see did you get sort of that look that you're going for. We actually think that they can do a series of, you know, patients in turns where they inject, they wait to see whether or not they are getting sort of that, you know, acute result that they're looking for and whether or not they need to make any other tweaks, you know, to sort of get what the outcome is. I think that today we're gonna get the benefit of the doubt on the duration, and so it's really about that acute performance. I don't know, Dustin, if you wanted to add anything? No, I think the other thing, Annabel, is how they integrated the practices. You've seen a lot of these product launches fail because they don't know how to charge for it, they don't know how to explain it. This is something that we're gonna invest in early on to make sure that when they get the product, they know exactly what the value is, how to charge patients for it, how to schedule them, and how to get the most satisfaction out of a two times a year neuromodulator. So we feel like it's not only just about the clinical and outcomes profile, but also about how to best integrate. If you look at our model, we don't wanna call on everyone. You've seen launches where they sample thousands and thousands of accounts, and the metric is to then determine how many of those then convert into successful practices. We wanna kinda go the other way, which is take the practices that believe in the value that we're driving, surround them with RHA, OPUL, and DAXI, and go deeper in those accounts. We feel like that's the strategy that wins, and focusing directly on how to make them successful as our partners versus dropping off a product and trying to expand it as quickly as possible. We think you can drive more value with the latter. Okay. Great. Thank you so much. Great. Thanks, Annabel. Your next question comes from the line of Balaji Prasad from Barclays. Your line is now open. Hi. Good afternoon. Thanks for the questions. Two from me. Firstly, on the competitive landscape, I would like to get your thoughts around Evolus extra strength Jeuveau. How do you think this would impact market dynamics, assuming that it comes in a couple of quarters after DAXI has been present? And how can you prevent any loss of market share, if at all, with a second toxin, maybe with similar claim to fame around durations? Second question is on biosimilar BOTOX and the delay that Viatris called out yesterday. Is there any reason to consider that this project could be shelved or delayed considering your partner's altered importance of biosimilar Znac? Thank you. Thanks, Balaji. I'll take the second one first, then hand it back to Dustin on the competitive landscape and stuff. On the Viatris side of it, you know, the delay there, we use the same drug substance manufacturing for both the biosimilar to BOTOX in our program. There's been a direct impact based on the delay of our approval for DaxibotulinumtoxinA for Injection, which has impacted, you know, that program. We continue to feel very encouraged. The teams continue to collaborate really well, move forward. We like what we're hearing from the agency about what the path forward looks like. That's really been the biggest impact. You know, hopefully, you know, with approval, that will put us on a much more deterministic timeframe, but that's related to the Viatris side of it. If you wanna talk about competitive landscape? Yeah. Thanks, Mark. So Balaji, I believe you're talking about the Evolus, you know, high dose, you know, toxin clinical program that they put together. That's what I'm talking about, yep. Yeah. If you look at this landscape is not new. The doses that were picked for the neuromodulators that have been in the market for decades were picked specifically because they drove the right efficacy and the right safety profile. You look at therapeutics being started, there would be a kind of lean towards if a higher dose product was more efficacious, you'd actually be better off in aesthetics having that because of the kinda combination of the therapeutic pricing. We feel that the high dose noise will be out there consistently. The fundamental fact is that DAXI is the first ever product to be formulated with the cell-penetrating peptide that stabilizes the product and delivers an efficacy profile with the same active amount of neuromodulator that is currently on the market today. We find it a lot to be noise. We think DAXI has proven throughout a large clinical profile programs, both in aesthetics, across multiple indications in aesthetics and in therapeutics, that this is a product that acts differently. It's not a dosing paradigm. We think there'll be noise out there, but if a larger dose product was more effective, we think that would've had kinda impact on the market already. Because they could have done that with a BOTOX or XEOMIN or all these other products that have chased those kind of double dose or higher dose studies as well. We feel really good about the uniqueness of DAXI and look forward to getting it to market. Thank you. Great. Thanks, Balaji. Your next question comes from the line of Vamil Divan from Mizuho Securities. Your line is now open. Great. Thanks for taking my questions, and I think most of mine have also been asked. Just to clarify, I know you can't say too much around the regulatory side of things, but you mentioned you're not gonna be giving the sort of, you know, play-by-play like you did before, but you will sort of be commenting on any material updates. I just wanna make sure we're clear 'cause we get a lot of questions on this issue. As you go through the process, would you be announcing sort of when they're coming for an inspection like you did last time? Would you announce when it's completed, or would you announce if there's any sort of findings from the inspection? Just trying to get a sense of what you're, at this point, what you consider the threshold for giving any updates. Yeah, no, Vamil, I appreciate that, and we certainly can appreciate sort of the desire from the investor community to kinda get whatever information that we're comfortable providing. Yeah, no, we're gonna kinda fall back to normal company policy, where we don't think it's appropriate to comment on ongoing FDA engagement. So things like, hey, has the inspection taken place or not? We wouldn't look at that as sort of routine or typical. Given that we now have a date that we're working to, a PDUFA date, our next expected communication would be once we receive, you know, official notification from the agency, regarding our CRL resubmission on or before the September eighth. Or if we were to receive something else material. You know, scheduling of an inspection, we would not deem to be material. We've already indicated that it's a Class 2 inspection and that we expect an inspection of our facility. We would not expect to give any additional updates between now and either a decision from the agency or our PDUFA date, whatever happens first, or in the event that we receive something that we deem to be material. Okay. All right, great. Thank you for that, detail. Maybe just one quick follow-up. I appreciate some of what you said earlier around sort of the macro concerns from inflation-wise and consumer spending. I know you're still a few months away from a potential launch, but I'm just curious how that might impact sort of how you're thinking about pricing in this market. We've seen your competitors raise price. Do you still see this as something where you'd come in, are you thinking of this, still on a premium sort of basis above where the current other toxins are priced? Or any sort of additional color on the pricing side just would be helpful as we think about how you're thinking about it a few months out. Sure. You know, we've been very thoughtful around sort of pricing. We've done a lot of market research. You know, we've spoken with a lot of physicians, too. Again, given the investment that we've made in innovation, we believe that based on the duration profile of the product, and how differentiated and unique it is, that it will command and warrant a premium in the marketplace. You know, I don't see us making any short-term decisions based on interest rate, you know, hikes or whatever, and the injectable category has proven to be fairly resilient. You know, we believe that there's room for us to charge a premium given the duration profile and that there's also an opportunity for practices to charge consumers more and offer frankly more value to them. Frankly, if anything in a market where interest rates rise and other things, we think, you know, there will be not an insignificant number of consumers that are gonna be looking to make sure that they get good value for the dollars that they spend. We, you know, are obviously not giving the details of our pricing strategy until launch for competitive reasons, but we think that we've got that right balance of charging a premium, practices making more margin, and consumers getting more value, and that will fit in today's market. Okay. All right. Thank you very much. Sure. Your next question comes from the line of Douglas Tsao from H.C. Wainwright. Your line is now open. Hi. Good afternoon. Thanks for taking the questions. I might have missed something earlier, but just in terms of the comments around some of the training needed, I'm just curious, you know, how long, 'cause it doesn't sound like, for each individual physician it's gonna necessarily take that long. How long do you think you'll be able to roll this out to sort of that initial group of customers, especially given the fact that there are a fair number of accounts that have had experience with the product during in the clinical trial? Thank you. Sure. No, great question, Doug. I think that, you know, while there's certainly, you know, 60 or so sites that were part of the clinical trial, you know, remember that they had to do all the injection per the prescribed protocol, and it was only for glabellar lines. We did some Phase II work in upper facial lines, but that was sort of a small group of only a handful, 4 or so. You know, even those that have experience with the product, they're gonna want to, you know, use it as they currently use other products, which is gonna be more broad. Given sort of that desire to use the product, get that feedback of how what's that, you know, sort of settled look after a couple of days, I think that they're probably gonna wanna cycle through that a little bit. That's why we're gonna take this in stepwise function, where it'll be that initial small group. We'll take some of those learnings and then roll it out into sort of a little bit bigger preview group, all with the focus on making sure that we get the right outcome. You know, we'll continue to update you as we move forward, but again, we think this is really the right strategy in this initial phase to make sure that we focus on outcomes, don't compromise that. You know, like I said, we've got a growing base of customers as we move forward that we'll be able to lean into. What will that initial group of customers be? Presumably that those that's gonna be significant overlap with the RHA customers right now? That's correct. Yeah. If you look at our strategy where we said we're targeting the higher end customers that are focused on, you know, outcomes and less on sort of pricing. That targeting is the same targeting that we've used for the RHA fillers. It will definitely be, you know, a majority of overlap between our RHA customers as we go into it. In terms of the timing of that, you know, we've said that it'll be this initial phase of call it a quarter or so with this initial group, and then we'll move into that preview group, which, you know, we'll kind of get a better feeling as to, you know, the learnings from that first group, how long that second phase will be. I think that's the kind of information that we'll be able to share as you think about your models once we get that feedback. Okay. That will be sort of the initial phase, then the preview phase, and then after that you would move into sort of a broader launch. That is correct. Okay, great. Thank you so much. Great. Thanks, Doug. Your next question comes from the line of Tim Lugo from William Blair. Your line is now open. Hi, team. This is John on for Tim. Thanks so much for taking our questions. Just two from us. First- Okay. Just wondering about how your latest views on how the growth profile for the RHA line will change next year, assuming that DAXI hits the market around year-end and you build out that franchise. Second, for the supplemental BLA, just wondering if you can give us any more color on the timelines for filing, assuming DAXI is approved. Is that gonna be something that's on the order of weeks or months or maybe something a little longer? Thanks. Why don't I take the second one first, John, and then I'll let Dustin hit the first one. The supplemental filing for cervical dystonia, we've already completed the entire clinical program. We've pulled together the information that we need to complete that submission, post the approval of DAXI botulinum toxin A for injection for glabellar lines. I would expect that the submission of that supplemental BLA will occur within a quarter post-launch. Then we completed a Phase II program in upper limb spasticity. We paused additional clinical programs in therapeutics during this phase, given the CRL, to preserve our cash runway. Once we file the CD, we get into market, then we'll kinda revisit, you know, sort of what's the next step that we wanna take on the therapeutics program. Then Dustin, I'll hand over the first one to you. Yeah. We remain really excited about the kinda long-term trajectory of the RHA® Collection, right? In talking now, we'll have four unique gels with two different indications and also further indications coming in the future. That coupled with, yes, the sales force will have a different priority in terms of adding DAXI in the bag, but we're also looking at what's the right time to expand reps, and then how do you look at this bundling opportunity between RHA and DAXI? How does RHA unlock potential for DAXI, and how does DAXI unlock potential for RHA? We feel really good about the trajectory. You've got a healthy growing dermal filler market in the United States. We've long talked about Teoxane having a 10% share kind of in the markets in which they compete ex-US, where they compete directly. Us having DAXI will continue allow us to kinda execute against that and potentially higher. We feel really good about the trajectory of all those products and really then adding OPUL to ensure the stickiness across the entire portfolio. We should be hitting on all cylinders with the launch of DAXI in combination of our training efforts and then kind of wrapping together the full portfolio. Thanks so much for the additional color. Great. Thanks, John. Thanks, John. Your next question comes from the line of Rohit Bhasin from Needham. Your line is now open. Hi, this is Rohit on for Serge. Thanks for taking my question. Can you talk a bit about how the rollout of the OPUL platform is going, and do you plan to phase out HintMD over time? Out of the 3,500 accounts, how many users are using the OPUL and how many HintMD platform? Thanks. Yeah, Rohit, this is Mark. You know, on the launch, if I kind of step back and, you know, look at what were the goals for this year. You know, we talked about becoming a payment facilitator as being an important step to have, you know, access to the source data to help provide the practice insights. We've evolved the system now to OPUL to where we have the payment facilitator function. We've also turned on the catalog as well, so that when checkouts are performed, these practices can, you know, flag the services that were provided, again, that we have source-level data. This year is about rolling out OPUL with that functionality, payback and catalog. You know, we're off to a good start in Q1. You know, we reported on our gross processing volume. We've seen, again, good growth in accounts that have it and the overall processing volume, and that'll be a metric that we continue to report out on, as a indicator of the health of the business. We've also talked about migrating the HintMD over to the OPUL platform, and so we're well underway, and we're just trying to make sure that we right-size that. You know, the HintMD platform has been very successful for those accounts that have adopted it. We just wanna make sure that as we shift people from HintMD over to OPUL, you know, that we don't break anything along the way or lose momentum in those accounts. You know, our expectation is that we will migrate, you know, most, if not all, of the HintMD accounts over to OPUL this year. We like that trajectory. You know, we talked also about, you know, turning on practice insights, you know, getting the catalog up and running and then, you know, continuing to drive, you know, further value in this platform. You know, we've not broken out the specific number of accounts that have the OPUL platform within the 3,500 accounts, nor have we broken out the RHA account separately. We've just said that between the two, we're in over 3,500 accounts, and we've been very sort of consistent and measured in the onboarding of new accounts on a quarterly basis. Great. Thank you. Great. Thanks, Rohit. Okay. There are no further questions at this time. I will turn the call back over to Mark for any final comments. Great. Thank you everyone for joining today's call. We have the upcoming William Blair healthcare conference. We look forward to seeing those of you there at that conference, who are gonna be in attendance. We welcome your request for meetings, you know, directly through us as well. Feel free to reach out to Jessica if you'd like to schedule some time. With that, I would like to thank all of you for participating in today's call. This concludes today's conference call. Thank you for participating. You may now disconnect.